Skin Cancer

Presenters highlight the possible solutions to communication between the scrubbed-in surgery team and outside help that could save time.

In a presentation at the current American College of Mohs Surgery meeting, Jennifer G. Powers, MD, highlights the needed improvement for immediate access to skin cancer care for VA patients, noting a 33 day average wait time compared to the VAs optimal goal of 28 days.

A poster at the 2022 American College of Mohs Surgery Annual Meeting examined the prevalence of bacterial organism colonization in Mohs wounds left to secondary intention.

Surgical site infections (SSIs) are a common adverse event after Mohs Micrographic Surgery, but researchers aimed to find out how the clinical features of gram-negative differ from their counterparts.

In this week’s Pointers with Dr Portela, the 208SkinDoc has posted several YouTube shorts on sunscreen. See what pearls he had to share on protecting skin from the sun.

With the number of melanoma cases among young adults on the rise, adherence to preventative measures could be critical to stemming the tide of increased incidences of this deadly skin disease.

Specifying histologic subtypes can drive better outcomes for patients and improve research.

Click here to answer this week's poll.

Savina Aneja, MD, highlights the importance of Melanoma Monday and gives clinical pearls on how to counsel patients, skin cancer screenings, and more.

Zoe Diana Draelos, MD, gives the details on sun protective clothing, including how it doesn't need to break the bank, how to test how protective clothing is, and a hat might be the most important piece of sun protection.

Data shows that the overall rate of melanoma diagnosis rose sixfold over the last 4 decades at a time when melanoma mortality stayed relatively stable.

Providing thorough, clear and actionable information is a key part of melanoma care; survey offers a look at where dermatologists can improve.

The American Academy of Dermatology’s survey finds more Americans say sun protection is more important than 5 years ago, but don’t understand how to protect themselves.

The Skin Cancer Foundation's mobile education program is set to cross the United States to both raise skin cancer awareness and provide free skin cancer screenings.

At the opening session of the Society of Dermatology Nurse Practitioners Annual Symposium, Kathleen Haycraft, DNP, FNP-BC, DCNP, FAANP, delved into the revolutionary and evolutionary advances shaping dermatology in 2022.

Scientists from Mount Sinai have reported that a mutation of the ARID2 gene may be a key factor in the risk of melanoma turning metastatic.

In her presentation at the recent American Academy of Dermatology (AAD) Annual Meeting, Anisha Patel, MD, FAAD, discusses challenging oncodermatology cases at the MD Anderson Cancer Center, University of Texas Health Science Center.

An expert debunks the myths surrounding sun-related factors associated with melanoma in a presentation at the 2022 American Academy of Dermatology Annual Meeting.

Dermatologists continue to be split on the pros and cons of skin cancer screening, from overdiagnosis to early detection of thin melanomas.

Mariam Totonchy, MD, and Chrysalyne D. Schmults, MD, MSCE, discuss best practices when caring for high-risk cSCC patients, including surgical vs nonsurgical options, imaging, and follow-up protocol.

Click here to answer this week's poll.

The FDA has approved the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma.

A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.

The addition of bempegaldesleukin to nivolumab did not significantly improve progression-free survival, objective response rate, or overall survival vs nivolumab alone in the frontline treatment of patients with unresectable or metastatic melanoma, missing the primary end points of the phase 3 PIVOT IO-001 trial.

Merck announced that pembrolizumab led to significant improvement in distant metastasis-free survival (DMFS) compared to placebo as adjuvant therapy for patients with resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 trial.